Compare Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) (SBS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) vs Travere Therapeutics Inc. Common Stock — how do they compare? Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) trades at $6.29 (market cap $22.64B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) is far larger — about 4.5× Travere Therapeutics Inc. Common Stock's market cap, and Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) pays a 0.52% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares) for 1 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SBS | TVTX | |
|---|---|---|
Market Cap | $22.64B | $5.02B |
Volume | 8,795,741 | 2,060,842 |
Sector | Utilities | Health |
52-Week High | $7.08 | $67.52 |
52-Week Low | $4.46 | $26.79 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $29.44B | $5.15B |
Dividend Yield | 0.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBS trades at $6.45, down 4.16% today, with a P/E of 13.54 and a net income margin of 19.71%. Recent earnings showed a Q2 2026 miss after two prior beats. Technical indicators are mixed, with a bullish moving average signal but bearish oscillators. The company reported 2025 revenue of $38.09B and net income of $8.46B, though 2026 projections indicate a slight decline in profit margin to 19.71%.
The outlook is cautious; while valuation metrics appear reasonable and profitability is strong, recent earnings volatility and a negative net cash flow projection for 2026 pose risks. Analyst sentiment is mixed with a 'Hold' consensus, suggesting limited near-term upside potential amid operational headwinds.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares)
Sabesp provides water supply and sewage services in the Brazilian state of São Paulo. Its shares trade in Brazil as SBSP3 and in the U.S. as NYSE-listed ADSs under SBS.
Read more on SBS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
